Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Gilead Seeks New CEO, Second Quarter Shows Stability

Executive Summary

Yescarta continued its growth trajectory, the HIV franchise showed solid sales growth and the hepatitis C franchise stayed steady – plus Gilead could jump to the head of the line in NASH.


Related Content

Akcea Expects Convenience Edge For Tegsedi, Despite Monitoring Requirements
Gilead And Novartis Unveil EU Marketing Plans For CAR-T Therapies, But Hurdles Remain
AbbVie HCV Revenue Surprises Again, But Falloff Is Coming
AbbVie HCV Revenue Surprises Again, But Falloff Is Coming
Harper, Hooper Exit As Amgen Revenues Rise
Interview: Measured Launch, Long Future For Gilead CAR-T In Europe
Yescarta One Of Few Gilead Bright Spots, And Now It Has A Competing CAR-T
New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib
Gilead's Biktarvy Approval Heightens HIV Competition With ViiV
Genfit's Enrollment Delay In NASH May Aid Intercept's First-To-Market Goal


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts